Coherus BioSciences (CHRS) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

CHRS Stock Forecast

Coherus BioSciences stock forecast is as follows: an average price target of $6.00 (represents a 294.74% upside from CHRS’s last price of $1.52) and a rating consensus of 'Hold', based on 5 wall street analysts offering a 1-year stock forecast.

CHRS Price Target

The average price target for Coherus BioSciences (CHRS) is $6.00 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $6.00 to $6.00. This represents a potential 294.74% upside from CHRS's last price of $1.52.

CHRS Analyst Ratings

Hold

According to 5 Wall Street analysts, Coherus BioSciences's rating consensus is 'Hold'. The analyst rating breakdown for CHRS stock is 0 'Strong Buy' (0.00%), 2 'Buy' (40.00%), 3 'Hold' (60.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Coherus BioSciences Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Dec 05, 2024	Colleen Kusy	Robert W. Baird	$6.00	$1.74	245.82%	294.74%
Nov 14, 2022		J.P. Morgan	$11.00	$7.79	41.21%	623.68%
Jun 13, 2022	Ashwani Verma	UBS	$7.00	$6.19	13.09%	360.53%

The latest Coherus BioSciences stock forecast, released on Dec 05, 2024 by Colleen Kusy from Robert W. Baird, set a price target of $6.00, which represents a 245.82% increase from the stock price at the time of the forecast ($1.74), and a 294.74% increase from CHRS last price ($1.52).

Coherus BioSciences Price Target by Period

	1M	3M	12M
# Anlaysts	1	1	1
Avg Price Target	$6.00	$6.00	$6.00
Last Closing Price	$1.52	$1.52	$1.52
Upside/Downside	294.74%	294.74%	294.74%

In the current month, the average price target of Coherus BioSciences stock is $6.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 294.74% increase as opposed to Coherus BioSciences's last price of $1.52. This month's average price target is down 0.00% compared to last quarter, and down 0.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Aug 16, 2024	UBS	Buy	Neutral	Downgrade
May 30, 2024	Cowen & Co.	Buy	Buy	Hold
May 10, 2024	H.C. Wainwright	Buy	Buy	Hold
Mar 28, 2023	UBS	Neutral	Buy	Upgrade
Jun 13, 2022	UBS		Neutral	Initialise
Apr 26, 2022	Zacks Investment Research		Hold	Upgrade
Apr 26, 2022	J.P. Morgan		Neutral	Downgrade

Coherus BioSciences's last stock rating was published by UBS on Aug 16, 2024. The company Downgrade its CHRS rating from "Buy" to "Neutral".

Coherus BioSciences Financial Forecast

Coherus BioSciences Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 17	Mar 16
Revenue	-	-	-	-	-	-	-	-	$91.52M	$74.57M	$58.72M	$32.44M	$45.35M	$45.42M	$60.15M	$60.12M	$73.37M	$82.50M	$87.64M	$83.03M	$110.42M	$113.55M	$135.67M	$116.18M	$123.86M	$111.68M	$83.43M	$37.10M	$161.00K	$12.36M
Avg Forecast	$58.50M	$45.45M	$41.00M	$49.00M	$44.15M	$58.98M	$62.06M	$81.70M	$96.89M	$81.78M	$50.47M	$46.29M	$47.69M	$56.69M	$62.04M	$69.54M	$82.61M	$90.69M	$87.04M	$96.20M	$114.89M	$124.01M	$102.52M	$119.44M	$125.09M	$100.72M	$64.63M	$36.96M	$143.23K	$10.51M
High Forecast	$70.35M	$54.66M	$49.30M	$64.27M	$65.47M	$60.81M	$74.63M	$81.70M	$111.89M	$81.78M	$60.70M	$55.67M	$57.35M	$56.69M	$62.04M	$69.54M	$82.61M	$90.69M	$87.04M	$96.20M	$114.89M	$124.01M	$102.52M	$119.44M	$125.09M	$100.72M	$64.63M	$36.96M	$171.87K	$12.61M
Low Forecast	$49.43M	$38.40M	$34.64M	$33.73M	$30.93M	$57.15M	$52.43M	$81.70M	$81.90M	$81.78M	$42.65M	$39.12M	$40.30M	$56.69M	$62.04M	$69.54M	$82.61M	$90.69M	$87.04M	$96.20M	$114.89M	$124.01M	$102.52M	$119.44M	$125.09M	$100.72M	$64.63M	$36.96M	$114.58K	$8.41M
# Analysts	1	1	1	1	5	4	3	3	6	3	3	3	4	4	4	4	3	3	3	3	3	3	8	11	7	11	7	7	17	8
Surprise %	-	-	-	-	-	-	-	-	0.94%	0.91%	1.16%	0.70%	0.95%	0.80%	0.97%	0.86%	0.89%	0.91%	1.01%	0.86%	0.96%	0.92%	1.32%	0.97%	0.99%	1.11%	1.29%	1.00%	1.12%	1.18%

Coherus BioSciences's average Quarter revenue forecast for Mar 24 based on 3 analysts is $81.70M, with a low forecast of $81.70M, and a high forecast of $81.70M. CHRS's average Quarter revenue forecast represents a -10.73% decrease compared to the company's last Quarter revenue of $91.52M (Dec 23).

Coherus BioSciences EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 17	Mar 16
# Analysts	1	1	1	1	5	4	3	3	6	3	3	3	4	4	4	4	3	3	3	3	3	3	8	11	7	11	7	7	17	8
EBITDA	-	-	-	-	-	-	-	-	$-68.36M	$-32.01M	$-34.54M	$-66.02M	$-49.48M	$-78.11M	$-42.68M	$-80.13M	$-39.10M	$-31.86M	$-23.28M	$-166.45M	$17.27M	$34.47M	$66.48M	$41.54M	$46.81M	$53.20M	$28.73M	$-15.10M	$-71.54M	$-63.83M
Avg Forecast	$-22.23M	$-17.27M	$-15.58M	$-18.62M	$-16.78M	$-22.42M	$-23.59M	$-88.66M	$-36.82M	$-31.08M	$-19.18M	$-70.09M	$-43.71M	$-21.61M	$-23.64M	$-55.41M	$-31.48M	$-34.56M	$-33.17M	$-5.84B	$-43.78M	$-47.26M	$-39.07M	$47.48M	$-47.67M	$-38.39M	$-24.63M	$-20.88M	$-62.66M	$-52.60M
High Forecast	$-18.79M	$-14.60M	$-13.17M	$-12.82M	$-11.75M	$-21.72M	$-19.93M	$-70.93M	$-31.12M	$-31.08M	$-16.21M	$-56.07M	$-34.97M	$-21.61M	$-23.64M	$-44.33M	$-31.48M	$-34.56M	$-33.17M	$-4.67B	$-43.78M	$-47.26M	$-39.07M	$56.97M	$-47.67M	$-38.39M	$-24.63M	$-16.70M	$-50.13M	$-42.08M
Low Forecast	$-26.74M	$-20.77M	$-18.74M	$-24.42M	$-24.88M	$-23.11M	$-28.36M	$-106.40M	$-42.53M	$-31.08M	$-23.07M	$-84.11M	$-52.45M	$-21.61M	$-23.64M	$-66.49M	$-31.48M	$-34.56M	$-33.17M	$-7.01B	$-43.78M	$-47.26M	$-39.07M	$37.98M	$-47.67M	$-38.39M	$-24.63M	$-25.05M	$-75.19M	$-63.11M
Surprise %	-	-	-	-	-	-	-	-	1.86%	1.03%	1.80%	0.94%	1.13%	3.62%	1.81%	1.45%	1.24%	0.92%	0.70%	0.03%	-0.39%	-0.73%	-1.70%	0.88%	-0.98%	-1.39%	-1.17%	0.72%	1.14%	1.21%

3 analysts predict CHRS's average Quarter EBITDA for Mar 21 to be $-5.84B, with a high of $-4.67B and a low of $-7.01B. This is -33927.77% lower than Coherus BioSciences's previous annual EBITDA (Dec 20) of $17.27M.

Coherus BioSciences Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 17	Mar 16
# Analysts	1	1	1	1	5	4	3	3	6	3	3	3	4	4	4	4	3	3	3	3	3	3	8	11	7	11	7	7	17	8
Net Income	-	-	-	-	-	-	-	-	$-79.65M	$-39.64M	$-42.87M	$-74.78M	$-66.25M	$-92.85M	$-56.29M	$-111.24M	$-51.52M	$-38.53M	$-29.90M	$-172.95M	$9.71M	$27.93M	$59.03M	$35.57M	$39.23M	$47.04M	$23.57M	$-20.00M	$-74.78M	$-65.39M
Avg Forecast	$-5.76M	$-5.76M	$-5.76M	$-5.76M	$-30.89M	$-18.82M	$-28.65M	$-98.66M	$-22.90M	$-44.97M	$-72.45M	$-77.99M	$-51.12M	$-82.31M	$-89.99M	$-61.65M	$-52.82M	$-39.73M	$-24.11M	$-6.07B	$24.68M	$42.04M	$33.20M	$40.65M	$80.89M	$54.62M	$-4.25M	$-27.67M	$-65.50M	$-53.88M
High Forecast	$-4.60M	$-4.60M	$-4.60M	$-4.38M	$-28.11M	$-15.03M	$-22.87M	$-78.93M	$-18.29M	$-35.90M	$-57.85M	$-62.39M	$-40.90M	$-82.31M	$-89.99M	$-49.32M	$-52.82M	$-39.73M	$-24.11M	$-4.86B	$24.68M	$42.04M	$33.20M	$48.78M	$80.89M	$54.62M	$-4.25M	$-22.13M	$-52.40M	$-43.10M
Low Forecast	$-7.28M	$-7.28M	$-7.28M	$-7.14M	$-33.68M	$-23.78M	$-36.19M	$-118.39M	$-28.93M	$-56.81M	$-91.53M	$-93.59M	$-61.35M	$-82.31M	$-89.99M	$-73.98M	$-52.82M	$-39.73M	$-24.11M	$-7.28B	$24.68M	$42.04M	$33.20M	$32.52M	$80.89M	$54.62M	$-4.25M	$-33.20M	$-78.60M	$-64.65M
Surprise %	-	-	-	-	-	-	-	-	3.48%	0.88%	0.59%	0.96%	1.30%	1.13%	0.63%	1.80%	0.98%	0.97%	1.24%	0.03%	0.39%	0.66%	1.78%	0.88%	0.48%	0.86%	-5.55%	0.72%	1.14%	1.21%

Coherus BioSciences's average Quarter net income forecast for Mar 21 is $-6.07B, with a range of $-7.28B to $-4.86B. CHRS's average Quarter net income forecast represents a -62630.28% decrease compared to the company's last Quarter net income of $9.71M (Dec 20).

Coherus BioSciences SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 17	Mar 16
# Analysts	1	1	1	1	5	4	3	3	6	3	3	3	4	4	4	4	3	3	3	3	3	3	8	11	7	11	7	7	17	8
SG&A	-	-	-	-	-	-	-	-	$48.95M	$48.22M	$45.14M	$49.15M	$53.62M	$44.83M	$51.28M	$48.75M	$50.05M	$39.92M	$40.34M	$39.39M	$37.69M	$31.98M	$34.05M	$35.35M	$36.07M	$31.83M	$36.46M	$32.68M	$18.80M	$11.40M
Avg Forecast	$33.45M	$25.99M	$23.44M	$28.02M	$25.24M	$33.72M	$35.48M	$50.06M	$55.40M	$46.76M	$28.86M	$39.57M	$27.27M	$32.42M	$35.47M	$31.28M	$47.24M	$51.85M	$49.77M	$55.01M	$65.69M	$70.91M	$58.62M	$40.40M	$71.52M	$57.59M	$36.95M	$21.13M	$81.89K	$9.39M
High Forecast	$40.22M	$31.25M	$28.19M	$36.75M	$37.44M	$34.77M	$42.67M	$60.07M	$63.98M	$46.76M	$34.70M	$47.49M	$32.79M	$32.42M	$35.47M	$37.54M	$47.24M	$51.85M	$49.77M	$55.01M	$65.69M	$70.91M	$58.62M	$48.48M	$71.52M	$57.59M	$36.95M	$21.13M	$98.27K	$11.27M
Low Forecast	$28.26M	$21.96M	$19.81M	$19.28M	$17.68M	$32.68M	$29.98M	$40.05M	$46.83M	$46.76M	$24.38M	$31.66M	$23.04M	$32.42M	$35.47M	$25.03M	$47.24M	$51.85M	$49.77M	$55.01M	$65.69M	$70.91M	$58.62M	$32.32M	$71.52M	$57.59M	$36.95M	$21.13M	$65.51K	$7.51M
Surprise %	-	-	-	-	-	-	-	-	0.88%	1.03%	1.56%	1.24%	1.97%	1.38%	1.45%	1.56%	1.06%	0.77%	0.81%	0.72%	0.57%	0.45%	0.58%	0.88%	0.50%	0.55%	0.99%	1.55%	229.60%	1.21%

Coherus BioSciences's average Quarter SG&A projection for Mar 24 is $50.06M, based on 3 Wall Street analysts, with a range of $40.05M to $60.07M. The forecast indicates a 2.27% rise compared to CHRS last annual SG&A of $48.95M (Dec 23).

Coherus BioSciences EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 17	Mar 16
# Analysts	1	1	1	1	5	4	3	3	6	3	3	3	4	4	4	4	3	3	3	3	3	3	8	11	7	11	7	7	17	8
EPS	-	-	-	-	-	-	-	-	$-0.71	$-0.00	$-0.49	$-0.94	$-0.85	$-1.19	$-0.73	$-1.44	$-0.67	$-0.49	$-0.40	$-2.37	$0.13	$0.39	$0.83	$0.50	$0.56	$0.67	$0.34	$-0.29	$-1.54	$-1.67
Avg Forecast	$-0.05	$-0.05	$-0.05	$-0.05	$-0.27	$-0.16	$-0.25	$-0.25	$-0.20	$-0.39	$-0.63	$-0.72	$-0.98	$-0.72	$-0.78	$-0.65	$-0.46	$-0.35	$-0.21	$-0.21	$0.21	$0.37	$0.29	$0.52	$0.70	$0.48	$-0.04	$-0.47	$-1.20	$-1.17
High Forecast	$-0.04	$-0.04	$-0.04	$-0.04	$-0.24	$-0.13	$-0.20	$-0.20	$-0.16	$-0.31	$-0.50	$-0.58	$-0.78	$-0.72	$-0.78	$-0.65	$-0.46	$-0.35	$-0.21	$-0.21	$0.21	$0.37	$0.29	$0.52	$0.70	$0.48	$-0.04	$-0.47	$-0.96	$-0.94
Low Forecast	$-0.06	$-0.06	$-0.06	$-0.06	$-0.29	$-0.21	$-0.31	$-0.32	$-0.25	$-0.49	$-0.79	$-0.91	$-1.24	$-0.72	$-0.78	$-0.65	$-0.46	$-0.35	$-0.21	$-0.21	$0.21	$0.37	$0.29	$0.52	$0.70	$0.48	$-0.04	$-0.47	$-1.44	$-1.40
Surprise %	-	-	-	-	-	-	-	-	3.57%	0.00%	0.78%	1.30%	0.87%	1.66%	0.93%	2.23%	1.46%	1.42%	1.90%	11.47%	0.60%	1.07%	2.87%	0.97%	0.79%	1.41%	-9.19%	0.62%	1.28%	1.43%

According to 3 Wall Street analysts, Coherus BioSciences's projected average Quarter EPS for Mar 21 is $-0.21, with a low estimate of $-0.21 and a high estimate of $-0.21. This represents a -259.00% decrease compared to CHRS previous annual EPS of $0.13 (Dec 20).

Coherus BioSciences Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
SPRO	Spero Therapeutics	$1.04	$10.00	861.54%	Buy
TIL	Instil Bio	$21.69	$150.00	591.56%	Hold
CHRS	Coherus BioSciences	$1.71	$6.00	250.88%	Hold
NXTC	NextCure	$0.90	$3.00	233.33%	Buy
CTMX	CytomX Therapeutics	$1.13	$3.47	207.08%	Buy
NUVB	Nuvation Bio	$2.81	$7.00	149.11%	Buy
ASMB	Assembly Biosciences	$14.28	$35.50	148.60%	Buy
ACHL	Achilles Therapeutics	$0.97	$2.00	106.19%	Buy
BOLT	Bolt Biotherapeutics	$0.54	$1.00	85.19%	Hold

CHRS Forecast FAQ

Is Coherus BioSciences a good buy?

No, according to 5 Wall Street analysts, Coherus BioSciences (CHRS) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 40.00% of CHRS's total ratings.

What is CHRS's price target?

Coherus BioSciences (CHRS) average price target is $6 with a range of $6 to $6, implying a 294.74% from its last price of $1.52. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Coherus BioSciences stock go up soon?

According to Wall Street analysts' prediction for CHRS stock, the company can go up by 294.74% (from the last price of $1.52 to the average price target of $6), up by 294.74% based on the highest stock price target, and up by 294.74% based on the lowest stock price target.

Can Coherus BioSciences stock reach $2?

CHRS's average twelve months analyst stock price target of $6 supports the claim that Coherus BioSciences can reach $2 in the near future.

What is Coherus BioSciences's current price target trend?

1 Wall Street analyst forecast a $6 price target for Coherus BioSciences (CHRS) this month, up 294.74% from its last price of $1.52. Compared to the last 3 and 12 months, the average price target increased by 294.74% and increased by 294.74%, respectively.

What are Coherus BioSciences's analysts' financial forecasts?

Coherus BioSciences's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $246.89M (high $282.61M, low $222.22M), average EBITDA is $-151M (high $-124M, low $-183M), average net income is $-177M (high $-145M, low $-212M), average SG&A $144.51M (high $174.95M, low $120.39M), and average EPS is $-0.934 (high $-0.775, low $-1.133). CHRS's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $193.95M (high $238.57M, low $156.2M), average EBITDA is $-73.712M (high $-59.364M, low $-90.671M), average net income is $-23.042M (high $-18.174M, low $-28.977M), average SG&A $110.9M (high $136.41M, low $89.31M), and average EPS is $-0.2 (high $-0.158, low $-0.252).

Did the CHRS's actual financial results beat the analysts' financial forecasts?

Based on Coherus BioSciences's last annual report (Dec 2023), the company's revenue was $257.24M, which missed the average analysts forecast of $275.44M by -6.61%. Apple's EBITDA was $-203M, beating the average prediction of $-157M by 29.28%. The company's net income was $-238M, beating the average estimation of $-218M by 8.97%. Apple's SG&A was $186.92M, beating the average forecast of $170.59M by 9.57%. Lastly, the company's EPS was $-2.53, beating the average prediction of $-1.939 by 30.46%. In terms of the last quarterly report (Dec 2023), Coherus BioSciences's revenue was $91.52M, missing the average analysts' forecast of $96.89M by -5.54%. The company's EBITDA was $-68.36M, beating the average prediction of $-36.825M by 85.63%. Coherus BioSciences's net income was $-79.653M, beating the average estimation of $-22.903M by 247.79%. The company's SG&A was $48.95M, missing the average forecast of $55.4M by -11.65%. Lastly, the company's EPS was $-0.71, beating the average prediction of $-0.199 by 257.16%